Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 4478 (miR-4478) is a small non-coding RNA molecule that regulates gene expression at the post-transcriptional level by binding to the 3′ untranslated region (UTR) of specific mRNAs, leading to their degradation or translational repression. In ovarian cancer, miR-4478 is typically downregulated and its reduced expression is associated with poor prognosis and increased resistance to radiation therapy. miR-4478 promotes radiosensitivity in ovarian cancer cells, at least partly by targeting the FUS gene (fused in sarcoma), which is involved in DNA damage repair and autophagy. Modulation of miR-4478 levels has been shown experimentally to alter cancer cell proliferation and response to irradiation, suggesting its potential as a therapeutic target and prognostic biomarker in oncology[1].
Functions via post-transcriptional gene silencing, acts by directly binding to the 3′ UTR of target mRNAs (such as FUS), leading to mRNA degradation or translation inhibition[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 4478 (miR-4478).